L’Enfant Plaza Hotel, Washington, DC, USA
Oct 5 2010 8:00AM - Oct 6 2010 5:00PM
CALL FOR ABSTRACTS Please submit all abstracts via email to Rachel Minnick, Program Developer Rachel.Minnick@diahome.org All abstracts must be received by August 17, 2010. Please provide all information in PowerPoint or MSWord format
This two-day conference will examine: • How to more efficiently develop T2DM medications • How to evaluate CV safety during DM drug development – preclinical and clinical approaches • Clinical implications and benefi ts of glycemic control • Therapies and targets for treatment of Diabetes Mellitus • Evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM • Novel trial design approaches to assessing CV safety • Clinical evidence that T2DM diabetic drugs can increase CV risk and potential mechanisms • Approaches to the clinical analysis of CV risk • Clinical approaches to Phase 3 development • Future approaches to assessing T2DM drug development and CV safety • Preclinical studies and the use of biomarkers to assess CV safety of new chemical entities Event Code: 10035
|
|